0.13Open0.14Pre Close14 Volume1.36K Open Interest11.00Strike Price175.00Turnover91.81%IV26.23%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.1321Delta0.1312Gamma87.70Leverage Ratio-0.0117Theta0.0004Rho11.58Eff Leverage0.0038Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet